FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2440701858> ?p ?o ?g. }

• W2440701858 endingPage "1787" @default.
• W2440701858 startingPage "1779" @default.
• W2440701858 abstract "Essentials•Antibodies to domain 1 of β2 glycoprotein I (aD1) are a subset of antiphospholipid antibodies.•We evaluated the added diagnostic value of an automated aD1 assay in antiphospholipid syndrome.•AD1 IgG correctly classifies patients at risk for thrombosis.•Agreement between aD1 and aβ2GPI IgG is high, limiting the added value of aD1 in our setting.Click to hear Professor de Groot's perspective on new mechanistic understanding in antiphospholipid syndromeSummary: BackgroundLaboratory diagnosis of antiphospholipid syndrome (APS) includes lupus anticoagulant (LAC), anticardiolipin (aCL) or anti‐β2 glycoprotein I (aβ2GPI) antibodies. Antibodies targeting domain 1 of β2GPI (aD1) constitute a pathogenic subset of autoantibodies.ObjectivesIn this cohort study, we determined the clinical performance characteristics, additional diagnostic value and the contribution to APS risk stratification of an automated aD1 assay.Patients/MethodsLAC, aCL, aβ2GPI and aD1 IgG were measured in 101 APS patients, 123 patients with autoimmune disorders, 82 diseased controls and 120 healthy controls. aD1 antibodies were detected by QUANTA Flash® Beta2GPI‐Domain 1 chemiluminescence immunoassay.ResultsWith a cut‐off value of 20.0 CU, the aD1 IgG assay identifies APS patients in a clinically affected patient cohort with a sensitivity of 53.5% and specificity of 98.8%. It implied a high odds ratio (OR) for clinical events (OR, 17.0; 95% confidence interval [CI], 7.1–40.5). aD1 IgG did not add diagnostic value to the formal aPL panel because aβ2GPI IgG was nearly as specific but more sensitive for APS (sensitivity 56.4%) with a higher OR for clinical events (36.2; 95% CI, 11.1–117.9). High aD1 titers identify triple‐positive patients and patients with thrombosis in a β2GPI‐dependent LAC‐positive population. Agreement between aD1 IgG and aβ2GPI IgG was high (positive and negative agreement 91.7% and 98.4%, respectively).ConclusionDetection of aD1 IgG correctly classifies patients at risk of thrombosis. However, the contribution of aD1 IgG to APS diagnosis and risk stratification depends upon the solid phase assays used for aCL and aβ2GPI detection. Essentials•Antibodies to domain 1 of β2 glycoprotein I (aD1) are a subset of antiphospholipid antibodies.•We evaluated the added diagnostic value of an automated aD1 assay in antiphospholipid syndrome.•AD1 IgG correctly classifies patients at risk for thrombosis.•Agreement between aD1 and aβ2GPI IgG is high, limiting the added value of aD1 in our setting. •Antibodies to domain 1 of β2 glycoprotein I (aD1) are a subset of antiphospholipid antibodies.•We evaluated the added diagnostic value of an automated aD1 assay in antiphospholipid syndrome.•AD1 IgG correctly classifies patients at risk for thrombosis.•Agreement between aD1 and aβ2GPI IgG is high, limiting the added value of aD1 in our setting. Click to hear Professor de Groot's perspective on new mechanistic understanding in antiphospholipid syndrome Laboratory diagnosis of antiphospholipid syndrome (APS) includes lupus anticoagulant (LAC), anticardiolipin (aCL) or anti‐β2 glycoprotein I (aβ2GPI) antibodies. Antibodies targeting domain 1 of β2GPI (aD1) constitute a pathogenic subset of autoantibodies. In this cohort study, we determined the clinical performance characteristics, additional diagnostic value and the contribution to APS risk stratification of an automated aD1 assay. LAC, aCL, aβ2GPI and aD1 IgG were measured in 101 APS patients, 123 patients with autoimmune disorders, 82 diseased controls and 120 healthy controls. aD1 antibodies were detected by QUANTA Flash® Beta2GPI‐Domain 1 chemiluminescence immunoassay. With a cut‐off value of 20.0 CU, the aD1 IgG assay identifies APS patients in a clinically affected patient cohort with a sensitivity of 53.5% and specificity of 98.8%. It implied a high odds ratio (OR) for clinical events (OR, 17.0; 95% confidence interval [CI], 7.1–40.5). aD1 IgG did not add diagnostic value to the formal aPL panel because aβ2GPI IgG was nearly as specific but more sensitive for APS (sensitivity 56.4%) with a higher OR for clinical events (36.2; 95% CI, 11.1–117.9). High aD1 titers identify triple‐positive patients and patients with thrombosis in a β2GPI‐dependent LAC‐positive population. Agreement between aD1 IgG and aβ2GPI IgG was high (positive and negative agreement 91.7% and 98.4%, respectively). Detection of aD1 IgG correctly classifies patients at risk of thrombosis. However, the contribution of aD1 IgG to APS diagnosis and risk stratification depends upon the solid phase assays used for aCL and aβ2GPI detection." @default.
• W2440701858 created "2016-06-24" @default.
• W2440701858 creator A5008510912 @default.
• W2440701858 creator A5065094545 @default.
• W2440701858 creator A5071705224 @default.
• W2440701858 date "2016-09-01" @default.
• W2440701858 modified "2023-10-14" @default.
• W2440701858 title "Role of anti‐domain 1‐β2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome" @default.
• W2440701858 cites W1541122820 @default.
• W2440701858 cites W1596249994 @default.
• W2440701858 cites W1977057127 @default.
• W2440701858 cites W1987991996 @default.
• W2440701858 cites W1992325618 @default.
• W2440701858 cites W1992631495 @default.
• W2440701858 cites W2001955212 @default.
• W2440701858 cites W2005750417 @default.
• W2440701858 cites W2006745686 @default.
• W2440701858 cites W2009045164 @default.
• W2440701858 cites W2014479232 @default.
• W2440701858 cites W2017573410 @default.
• W2440701858 cites W2035160119 @default.
• W2440701858 cites W2041919675 @default.
• W2440701858 cites W2043764018 @default.
• W2440701858 cites W2046838002 @default.
• W2440701858 cites W2054330426 @default.
• W2440701858 cites W2056423224 @default.
• W2440701858 cites W2058189064 @default.
• W2440701858 cites W2061375905 @default.
• W2440701858 cites W2069797332 @default.
• W2440701858 cites W2076776609 @default.
• W2440701858 cites W2084085262 @default.
• W2440701858 cites W2086581793 @default.
• W2440701858 cites W2101326680 @default.
• W2440701858 cites W2101831374 @default.
• W2440701858 cites W2113891001 @default.
• W2440701858 cites W2119085128 @default.
• W2440701858 cites W2119266650 @default.
• W2440701858 cites W2120945493 @default.
• W2440701858 cites W2123051496 @default.
• W2440701858 cites W2126076676 @default.
• W2440701858 cites W2136178364 @default.
• W2440701858 cites W2141738739 @default.
• W2440701858 cites W2142444723 @default.
• W2440701858 cites W2143086319 @default.
• W2440701858 cites W2143891179 @default.
• W2440701858 doi "https://doi.org/10.1111/jth.13389" @default.
• W2440701858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27314634" @default.
• W2440701858 hasPublicationYear "2016" @default.
• W2440701858 type Work @default.
• W2440701858 sameAs 2440701858 @default.
• W2440701858 citedByCount "66" @default.
• W2440701858 countsByYear W24407018582016 @default.
• W2440701858 countsByYear W24407018582017 @default.
• W2440701858 countsByYear W24407018582018 @default.
• W2440701858 countsByYear W24407018582019 @default.
• W2440701858 countsByYear W24407018582020 @default.
• W2440701858 countsByYear W24407018582021 @default.
• W2440701858 countsByYear W24407018582022 @default.
• W2440701858 countsByYear W24407018582023 @default.
• W2440701858 crossrefType "journal-article" @default.
• W2440701858 hasAuthorship W2440701858A5008510912 @default.
• W2440701858 hasAuthorship W2440701858A5065094545 @default.
• W2440701858 hasAuthorship W2440701858A5071705224 @default.
• W2440701858 hasBestOaLocation W24407018581 @default.
• W2440701858 hasConcept C126322002 @default.
• W2440701858 hasConcept C156957248 @default.
• W2440701858 hasConcept C159654299 @default.
• W2440701858 hasConcept C163764329 @default.
• W2440701858 hasConcept C203014093 @default.
• W2440701858 hasConcept C2776874634 @default.
• W2440701858 hasConcept C2780022809 @default.
• W2440701858 hasConcept C2780420688 @default.
• W2440701858 hasConcept C2780898057 @default.
• W2440701858 hasConcept C71924100 @default.
• W2440701858 hasConcept C90924648 @default.
• W2440701858 hasConceptScore W2440701858C126322002 @default.
• W2440701858 hasConceptScore W2440701858C156957248 @default.
• W2440701858 hasConceptScore W2440701858C159654299 @default.
• W2440701858 hasConceptScore W2440701858C163764329 @default.
• W2440701858 hasConceptScore W2440701858C203014093 @default.
• W2440701858 hasConceptScore W2440701858C2776874634 @default.
• W2440701858 hasConceptScore W2440701858C2780022809 @default.
• W2440701858 hasConceptScore W2440701858C2780420688 @default.
• W2440701858 hasConceptScore W2440701858C2780898057 @default.
• W2440701858 hasConceptScore W2440701858C71924100 @default.
• W2440701858 hasConceptScore W2440701858C90924648 @default.
• W2440701858 hasIssue "9" @default.
• W2440701858 hasLocation W24407018581 @default.
• W2440701858 hasLocation W24407018582 @default.
• W2440701858 hasOpenAccess W2440701858 @default.
• W2440701858 hasPrimaryLocation W24407018581 @default.
• W2440701858 hasRelatedWork W1829912953 @default.
• W2440701858 hasRelatedWork W2086581793 @default.
• W2440701858 hasRelatedWork W2101875571 @default.
• W2440701858 hasRelatedWork W2108731342 @default.
• W2440701858 hasRelatedWork W2146466204 @default.
• W2440701858 hasRelatedWork W2610682911 @default.
• W2440701858 hasRelatedWork W3021852519 @default.

• next